Tag Archives: Clinical trials

NMPA’s CMDE Opens Public Consultation on Draft Review Guidelines for AI Multi‑Disease Decision Devices and Deep Brain Stimulation Systems – Standardized Review Pathways Signal Next Phase of China MedTech Regulation

Leave a reply

Beijing, China – 15 Sep 2026 – The Center for Medical Device Evaluation (CMDE) of China’s National Medical Products Administration (NMPA) announced a public consultation on two draft registration review guidelines — the Guidelines for Clinical Evaluation and Registration Review of AI‑Assisted Multi‑Disease Decision‑Making Medical Devices (Draft for Comments) and the Guidelines for Clinical Evaluation and Registration Review of Implantable Deep Brain Stimulation (DBS) Systems (Draft for Comments) — with feedback due by 14 October 2026.

Consultation Snapshot

ItemDetail
AgencyCMDE, under the National Medical Products Administration (NMPA), China
ActionPublic solicitation of opinions on two draft technical review guidelines
Document 1AI‑assisted multi‑disease decision‑making medical devices – clinical evaluation & registration review
Document 2Implantable deep brain stimulation (DBS) systems – clinical evaluation & registration review
Notice Date15 September 2026
Comment Deadline14 October 2026, via email using the prescribed feedback form and subject‑line naming convention
Original Noticecmde.org.cn (published 16 September 2026)

Guideline Scope & Submission Channels

  • Document 1 – AI Multi‑Disease Decision Devices: Targets software‑based devices that assist clinical decision‑making across multiple diseases, defining clinical evaluation and registration review requirements. Detailed technical provisions were not disclosed in the notice itself; the full draft is available for download from CMDE.
  • Document 2 – Implantable DBS Systems: Sets out clinical evaluation and registration review requirements for implantable deep brain stimulation systems, a class of active implantable neurostimulation devices.
  • Submission Format: Comments must be filed via the official feedback form (Annex 3) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
  • Contacts – AI Guideline: Wang Zehua, Jiang Yan, Dong Zheng (wangzh@cmde.org.cn, jiangyan@cmde.org.cn, dongzheng@cmde.org.cn).
  • Contacts – DBS Guideline: Cui Xinyue, Guo Jiaying, Jin Yaxi (cuixy@cmde.org.cn, guojy@ydcmdei.org.cn, jinyx@cmde.org.cn) — with a Shanghai contact number indicating involvement of CMDE’s Yangtze River Delta branch.

Sector Background

  • AI as a Medical Device (SaMD): China has progressively built a review framework for AI‑enabled diagnostic software. Extending dedicated guidance to multi‑disease decision support reflects the regulator’s response to algorithms that synthesize patient data across indications rather than addressing a single disease — a materially more complex clinical evaluation problem.
  • Deep Brain Stimulation: DBS is an established implantable therapy for movement disorders such as Parkinson’s disease, with China’s market served by both global manufacturers (Medtronic, Abbott, Boston Scientific) and domestic players (PINS Medical, SceneRay).
  • Guideline System: CMDE technical review guidelines standardize registration dossiers and evaluation criteria; public consultation is the customary step before guidelines are finalized and take effect.

Market Impact & Outlook

  • Regulatory Clarity: Codified evaluation criteria for AI decision‑support software and implantable neurostimulators reduce approval uncertainty for developers and shorten pre‑submission negotiations.
  • AI‑MedTech Landscape: Sponsors of multi‑disease AI platforms — including hospital‑affiliated developers and health‑AI startups — should benchmark their clinical evidence strategies against the draft before the final guideline lands.
  • Neuromodulation Standardization: A dedicated DBS guideline aligns China’s review expectations with the maturity of its neurostimulation market, benefiting both multinationals and domestic manufacturers pursuing registration or next‑generation product iterations.
  • Participation Window: Industry stakeholders have until 14 October 2026 to shape the final requirements — an opportunity to flag practical concerns on clinical evaluation design, real‑world evidence, and post‑market obligations.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of draft guidelines, and their potential impact on medical device registration in China. The drafts are subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916105408164.html

China’s CDE Opens Public Consultation on Technical Guidelines for Anti‑Tuberculosis Drug Clinical Trials – One‑Month Comment Window on Draft Framework

Leave a reply

Beijing, China – 09 Sep 2026 – The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has released for public comment the Technical Guidelines for Clinical Trials of Anti‑Tuberculosis Drugs (Draft for Comments), a regulatory framework aimed at meeting the development needs of innovative anti‑tuberculosis (TB) drugs. The consultation is open to all sectors of society, with a one‑month feedback window from the date of publication; comments may be submitted to zhaiy@cde.org.cn and chengjw@cde.org.cn.

Regulatory Milestone

ItemDetail
AgencyCenter for Drug Evaluation (CDE), NMPA (China)
Action TypePublic consultation on draft technical guideline
DocumentTechnical Guidelines for Clinical Trials of Anti‑Tuberculosis Drugs (Draft for Comments)
PurposeAddress the R&D needs of innovative anti‑TB drugs and standardize clinical trial design and conduct
Issue Date9 September 2026
Comment PeriodOne month from publication (closing circa 9 October 2026)
Feedback Channelszhaiy@cde.org.cn; chengjw@cde.org.cn
Next StepsRevision and finalization of the guideline following review of public comments – detailed timeline Not disclosed

Guideline Scope & Policy Context

  • Objective: The draft was prepared by the CDE specifically “to meet the development needs of innovative anti‑pulmonary tuberculosis drugs,” signaling dedicated regulatory guidance for a therapeutic area historically underserved by tailored trial standards.
  • Consultation Approach: The CDE explicitly invites stakeholders across industry, academia, and the public to submit recommendations, with feedback to be incorporated in subsequent refinement of the guideline.
  • Specific Technical Provisions: Detailed trial design requirements, endpoint definitions, and population criteria in the draft – Not disclosed in the announcement itself; full text available via the CDE consultation posting.
  • Regulatory Pattern: The move extends China’s steady build‑out of disease‑specific technical guideline systems, giving sponsors earlier clarity on evidentiary expectations for anti‑TB clinical programs.

Clinical & Disease Context

  • Disease Burden: Tuberculosis remains among the world’s leading infectious‑disease causes of mortality, with China carrying one of the largest national TB burdens globally – underpinning sustained demand for innovative anti‑TB therapeutics.
  • Unmet Need: Drug‑resistant TB, lengthy treatment durations, and tolerability limitations of existing regimens continue to drive R&D toward new mechanisms and shorter, more effective combinations.
  • Trial Complexity: Anti‑TB trials involve distinct challenges – bacteriological endpoints, long follow‑up, relapse assessment, and combination‑regimen design – making standardized technical guidance a meaningful de‑risking tool for sponsors.

Market Impact & Outlook

  • Sponsor Implications: For domestic and multinational developers of anti‑TB candidates, finalized guidelines should reduce regulatory uncertainty in trial design and support more predictable review pathways in China.
  • Innovation Signal: Disease‑specific guidance reinforces the CDE’s broader policy direction of channeling structured support toward high‑unmet‑need infectious disease innovation.
  • Industry Participation: With a defined one‑month window, affected companies are expected to mobilize clinical, regulatory, and legal teams to shape provisions that will govern future TB trial submissions.
  • Final Guideline Timing: Publication date of the finalized version – Not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization of the Technical Guidelines for Clinical Trials of Anti‑Tuberculosis Drugs, associated regulatory timelines, and the implications for clinical development programs. The draft remains subject to change based on public feedback; actual outcomes may differ due to regulatory, technical, and policy considerations.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/ed1b82a54ba2a669d8f1af21a100ce17

CDE Seeks Input on Multivalent Vaccine Clinical Trial Q&A Guidelines

Leave a reply

Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) has released for public comment a draft Q&A document accompanying its Technical Guidelines for Clinical Trials of Multivalent Vaccines, aiming to refine regulatory standards for combination vaccine development by addressing common questions encountered in clinical research, with a comment window of one month from publication.

Consultation Snapshot

AttributeDetail
DocumentQ&A Document of the Technical Guidelines for Clinical Trials of Multivalent Vaccines (Draft for Comments)
Issuing bodyCenter for Drug Evaluation (CDE), NMPA
BasisPublished Technical Guidelines for Clinical Trials of Multivalent Vaccines
PurposeAddress common issues and further refine regulatory standards for combination vaccine clinical R&D
Comment periodOne month from publication (Sept 4, 2026)
Contactsliuyalin@cde.org.cn; pany@cde.org.cn; suy@cde.org.cn

Regulatory Context

Multivalent vaccines—known in Chinese regulatory parlance as “多联疫苗,” or combination vaccines—deliver antigens against multiple pathogens in a single formulation, exemplified by products such as the pentavalent DTP-IPV-Hib vaccine. Combination vaccines raise distinctive clinical trial questions that single-antigen products do not: immune interference between components, comparability with co-administered or predecessor vaccines, choice of immunobridging strategies, and consistency of batch-to-batch immunogenicity across multiple antigens. The CDE’s underlying guideline established the framework for such trials; the new Q&A document drills into recurring issues sponsors face when designing programs, offering granular interpretation that converts principle-level text into actionable standards for trial design, endpoint selection and submission packages.

Market Impact Analysis

For China’s fast-growing vaccine sector, the Q&A document lowers a key source of development uncertainty. Domestic manufacturers—several of which are pursuing combination vaccines to upgrade beyond single-antigen pediatric products—have faced ambiguity on how much comparability data regulators expect against licensed combination or component vaccines, and on acceptable immunobridging pathways. Clarified answers should compress pre-submission negotiation cycles, reduce the risk of costly trial redesigns, and give sponsors firmer ground for portfolio planning in pediatric and adult combination products.

The timing is notable: China’s vaccine market is undergoing consolidation and technological upgrading following the rollout of the Vaccine Administration Law, and combination vaccines represent one of the clearest premium segments where domestic players still trail imported pentavalent and hexavalent products. By refining guidance now, the CDE is supporting the domestic pipeline’s ability to compete in high-value multivalent formulations—an area with strong public health rationale, since combination vaccines improve immunization coverage and reduce injection burden for infants.

The one-month comment window, standard for CDE guideline consultations, suggests a near-term finalization timeline, with the final Q&A potentially in force before mid-2027.

Forward-Looking Statement

Industry participants are expected to submit feedback to the CDE’s designated contacts before the deadline in early October 2026, with the final Q&A document likely issued after the agency reviews and incorporates comments. Once adopted, the clarified standards should accelerate clinical trial initiation and review for combination vaccine candidates, and market watchers will look for specificity on immune-interference evaluation, comparability requirements against licensed products, and immunobridging acceptance criteria—the provisions most likely to shape development costs and timelines. The document also signals continued build-out of China’s vaccine regulatory toolkit, with future refinements anticipated as domestic multivalent candidates advance into late-stage trials and registration.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/bb2cfb685e7dde58e2dbc39b09f1dd3d